Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,323 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No medication Clear all
Completed No phase listed Observational Accepts healthy volunteers

Texas Family Health Patterns: A Study Across Generations

NCT02438254
View directory record Official record
Conditions
Alcohol and Other Drug Use Disorders
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 30 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Telephone Counseling for Tobacco Cessation

NCT01489579
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Telephone Counseling for Tobacco Cessation, Usual Care
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Phase 3 Interventional Results available

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Phase 3 Interventional

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

NCT00277043
View directory record Official record
Conditions
Supportive, Ill-defined Sites
Interventions
paclitaxel, docetaxel, taxane, taxane
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Improving Flexibility With a Mindbody Approach

NCT01066325
View directory record Official record
Conditions
General Low Back Hip and Hamstring Flexibility
Interventions
Neuro Emotional Technique, Stretching Instruction
Behavioral · Other
Lead sponsor
Parker Research Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 16, 2026, 3:36 AM EDT
Terminated Phase 2 Interventional

Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

NCT02997189
View directory record Official record
Conditions
Cisplatin Induced Hearing Loss
Interventions
OTO-104
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
6 Months to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Not applicable Interventional

Primary Care Clinician Commitments to Choosing Wisely®

NCT02247050
View directory record Official record
Conditions
Health Services Misuse, Physician's Practice Patterns, Guideline Adherence, Unnecessary Procedures, Health Care Costs
Interventions
Commitment invitation
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Ann Arbor, Michigan • Brighton, Michigan • Canton, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 16, 2026, 3:36 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)

NCT05288023
View directory record Official record
Conditions
Resistance Bacterial, Morality, Child Health, Implementation
Interventions
Azithromycin for Oral Suspension
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month and older
Enrollment
169,707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 16, 2026, 3:36 AM EDT
Withdrawn Not applicable Interventional

Bowel Preparation in Minimally Invasive Gynecologic Surgery

NCT06820359
View directory record Official record
Conditions
Gynecologic Disease
Interventions
Bowel Preparation, No bowel preparation
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Detroit, Michigan • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Phase 4 Interventional

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

NCT04276259
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
Drug · Device
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 16, 2026, 3:36 AM EDT
Recruiting Early Phase 1 Interventional

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

NCT06615596
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
Behavioral · Drug · Procedure
Lead sponsor
China National Center for Cardiovascular Diseases
Government
Eligibility
18 Years and older
Enrollment
3,160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Not applicable Interventional Results available

Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF)

NCT05275920
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Best Practice Alert (BPA), In-Basket Message
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2,211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Phase 2 Interventional Results available

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

NCT02150213
View directory record Official record
Conditions
Adrenocortical Adenoma, Endometrial Stromal Sarcomas
Interventions
MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram, Biopsy, BGG492
Procedure · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Tallahassee, Florida • Baltimore, Maryland • Hoffman, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Phase 2 Interventional

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

NCT05714969
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Gainesville, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 16, 2026, 3:36 AM EDT
Terminated Phase 1Phase 2 Interventional

Default BP Medication Intensification

NCT01994408
View directory record Official record
Conditions
Hypertension
Interventions
default intensification
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 16, 2026, 3:36 AM EDT
Recruiting Phase 4 Interventional

CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma

NCT07241117
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Implementation bundle
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

By Potentially Adding a Century Old Therapeutic Measure to Pain Treatment Regimens Called Osteopathic Manipulative Treatment, Can Help Decrease Muscle and Bone Pain and the Usage of Opioid Pain Medication.

NCT06930196
View directory record Official record
Conditions
Osteopathic Manipulative Treatment
Interventions
Counterstrain, Muscle Energy, High Velocity Low Amplitude, The Ultralign SA201 used for measuring tissue texture changes, IsoTouch
Other · Device
Lead sponsor
Skagit Regional Health
Other
Eligibility
18 Years to 65 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 16, 2026, 3:36 AM EDT
Withdrawn Phase 4 Interventional

ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

NCT07169162
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
ADZENYS XR-ODT, Placebo Oral Tablet
Drug
Lead sponsor
Aytu BioPharma, Inc.
Industry
Eligibility
4 Years to 5 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 16, 2026, 3:36 AM EDT
Recruiting Phase 2 Interventional

Palbociclib and Pembrolizumab In Central Nervous System Metastases

NCT02896335
View directory record Official record
Conditions
Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
Interventions
Palbociclib, Pembrolizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Not applicable Interventional Results available

Patient Centered Health Technology Medication Adherence Program for African American Hypertensives

NCT03454308
View directory record Official record
Conditions
Hypertension, Medication Non-Adherence
Interventions
SMASH, Enhanced SC
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 59 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 16, 2026, 3:36 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Determining the Necessity for Postoperative Antibiotics After Salivary Stent Placement

NCT03333408
View directory record Official record
Conditions
Salivary Duct
Interventions
Postoperative Oral Antibiotics (Clindamycin or Augmentin)
Drug
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 16, 2026, 3:36 AM EDT
Completed Not applicable Interventional

Antibiotic Prophylaxis With Routine Ureteral Stent Removal

NCT02944825
View directory record Official record
Conditions
Urolithiasis, UTI
Interventions
Ciprofloxacin, trimethoprim/sulfamethoxazole, No Intervention
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 16, 2026, 3:36 AM EDT
Withdrawn Phase 4 Interventional

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

NCT03093740
View directory record Official record
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
Zepatier, Zepatier plus Sofosbuvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 16, 2026, 3:36 AM EDT